TMCI

$1.46

Market ClosedAs of Mar 17, 8:00 PM UTC

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.46
Potential Upside
5%
Whystock Fair Value$1.53
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stab...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$94.30M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.77
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-58.94%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.96

Recent News

Moby
Feb 28, 2026

Treace Medical Concepts, Inc. Q4 2025 Earnings Call Summary

Moby summary of Treace Medical Concepts, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
GuruFocus.com
Feb 27, 2026

Treace Medical Concepts Inc (TMCI) Q4 2025 Earnings Call Highlights: Navigating Challenges with ...

Despite a revenue dip, Treace Medical Concepts Inc (TMCI) focuses on product innovation and market expansion to drive future growth.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Feb 27, 2026

Treace Medical Concepts Q4 Earnings Call Highlights

Treace Medical Concepts (NASDAQ:TMCI) management told investors it is entering what it called a “transformational phase,” expanding beyond its historical Lapiplasty focus to become a broader “comprehensive bunion solutions company.” On the company’s fourth quarter and full-year 2025 earnings call, e

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Associated Press Finance
Feb 27, 2026

Treace Medical Concepts: Q4 Earnings Snapshot

The Ponte Vedra, Florida-based company said it had a loss of 15 cents per share. Losses, adjusted to extinguish debt, were 12 cents per share. The results beat Wall Street expectations.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Feb 25, 2026

UFP Technologies (UFPT) Q4 Earnings Top Estimates

UFP (UFPT) delivered earnings and revenue surprises of +7.81% and -1.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
TMCI Stock Analysis & Real-Time Data | Whystock